BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 8445945)

  • 21. Resistance of t(17;19)-acute lymphoblastic leukemia cell lines to multiagents in induction therapy.
    Watanabe A; Inukai T; Kagami K; Abe M; Takagi M; Fukushima T; Fukushima H; Nanmoku T; Terui K; Ito T; Toki T; Ito E; Fujimura J; Goto H; Endo M; Look T; Kamps M; Minegishi M; Takita J; Inaba T; Takahashi H; Ohara A; Harama D; Shinohara T; Somazu S; Oshiro H; Akahane K; Goi K; Sugita K
    Cancer Med; 2019 Sep; 8(11):5274-5288. PubMed ID: 31305009
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunophenotypic cell lineage and in vitro cellular drug resistance in childhood relapsed acute lymphoblastic leukaemia.
    Kaspers GJ; Wijnands JJ; Hartmann R; Huismans L; Loonen AH; Stackelberg A; Henze G; Pieters R; Hählen K; Van Wering ER; Veerman AJ
    Eur J Cancer; 2005 Jun; 41(9):1300-3. PubMed ID: 15869873
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug combination testing in acute lymphoblastic leukemia using the MTT assay.
    Kaspers GJ; Veerman AJ; Pieters R; Van Zantwijk I; Hählen K; Van Wering ER
    Leuk Res; 1995 Mar; 19(3):175-81. PubMed ID: 7700079
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential methotrexate resistance in childhood T- versus common/preB-acute lymphoblastic leukemia can be measured by an in situ thymidylate synthase inhibition assay, but not by the MTT assay.
    Rots MG; Pieters R; Kaspers GJ; van Zantwijk CH; Noordhuis P; Mauritz R; Veerman AJ; Jansen G; Peters GJ
    Blood; 1999 Feb; 93(3):1067-74. PubMed ID: 9920857
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG).
    van der Does-van den Berg A; van Wering ER; Suciu S; Solbu G; van 't Veer MB; Rammeloo JA; de Koning J; van Zanen GE
    Am J Pediatr Hematol Oncol; 1989; 11(2):125-33. PubMed ID: 2665546
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The influence of intracellular idarubicin and daunorubicin levels on drug cytotoxicity in childhood acute leukemia.
    Styczyński J; Wysocki M; Debski R; Kurylak A; Balwierz W; Rokicka-Milewska R; Matysiak M; Balcerska A; Kowalczyk J; Wachowiak J; Sońta-Jakimczyk D; Chybicka A
    Acta Biochim Pol; 2002; 49(1):99-107. PubMed ID: 12136962
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypoxanthine-guanine phosphoribosyl-transferase in childhood leukemia: relation with immunophenotype, in vitro drug resistance and clinical prognosis.
    Pieters R; Huismans DR; Loonen AH; Peters GJ; Hählen K; van der Does-van den Berg A; van Wering ER; Veerman AJ
    Int J Cancer; 1992 May; 51(2):213-7. PubMed ID: 1568789
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Raised intracellular glutathione levels correlate with in vitro resistance to cytotoxic drugs in leukaemic cells from patients with acute lymphoblastic leukemia.
    Maung ZT; Hogarth L; Reid MM; Proctor SJ; Hamilton PJ; Hall AG
    Leukemia; 1994 Sep; 8(9):1487-91. PubMed ID: 8090028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of cytotoxicity by flow cytometric drug sensitivity assay in childhood T-cell acute lymphoblastic leukemia.
    Savaşan S; Buck S; Ozdemir O; Hamre M; Asselin B; Pullen J; Ravindranath Y
    Leuk Lymphoma; 2005 Jun; 46(6):833-40. PubMed ID: 16019527
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relation of 5'-nucleotidase and phosphatase activities with immunophenotype, drug resistance and clinical prognosis in childhood leukemia.
    Pieters R; Huismans DR; Loonen AH; Peters GJ; Hählen K; van der Does-van den Berg A; van Wering ER; Veerman AJ
    Leuk Res; 1992 Sep; 16(9):873-80. PubMed ID: 1405718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study.
    Kaspers GJ; Smets LA; Pieters R; Van Zantwijk CH; Van Wering ER; Veerman AJ
    Blood; 1995 Feb; 85(3):751-6. PubMed ID: 7833478
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical impact of in vitro cellular drug resistance on childhood acute lymphoblastic leukemia in Taiwan.
    Chen SH; Yang CP; Jaing TH; Hung IJ; Shih LY; Ho PC; Lee WI; Huang JL
    Leuk Lymphoma; 2012 Aug; 53(8):1536-42. PubMed ID: 22260162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myeloid antigen co-expression in childhood acute lymphoblastic leukaemia: relationship with in vitro drug resistance.
    Den Boer ML; Kapaun P; Pieters R; Kazemier KM; Janka-Schaub GE; Veerman AJ
    Br J Haematol; 1999 Jun; 105(4):876-82. PubMed ID: 10554796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood.
    Kaspers GJ; Pieters R; Van Zantwijk CH; De Laat PA; De Waal FC; Van Wering ER; Veerman AJ
    Br J Cancer; 1991 Sep; 64(3):469-74. PubMed ID: 1911186
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sensitivity of primary clonogenic blasts from acute lymphoblastic leukemia patients to an activated cyclophosphamide, viz., mafosfamide.
    Uckun FM; Chandan-Langlie M; Dockham PA; Aeppli D; Sladek NE
    Leuk Lymphoma; 1994 May; 13(5-6):417-28. PubMed ID: 8069187
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two groups of Philadelphia chromosome-positive childhood acute lymphoblastic leukemia classified by pretreatment multidrug sensitivity or resistance in in vitro testing.
    Hongo T; Okada S; Inoue N; Yamada S; Yajima S; Watanabe C; Fujii Y; Horikoshi Y
    Int J Hematol; 2002 Oct; 76(3):251-9. PubMed ID: 12416736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia.
    Stams WA; den Boer ML; Beverloo HB; Meijerink JP; van Wering ER; Janka-Schaub GE; Pieters R
    Clin Cancer Res; 2005 Apr; 11(8):2974-80. PubMed ID: 15837750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
    Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M
    Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro chemosensitivity of lymphoblasts at relapse in childhood leukemia using the MTT assay.
    Hongo T; Fujii Y
    Int J Hematol; 1991 Jun; 54(3):219-30. PubMed ID: 1747457
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical relevance of in vitro drug resistance testing in childhood acute lymphoblastic leukemia: the state of the art.
    Pieters R; Kaspers GJ; Klumper E; Veerman AJ
    Med Pediatr Oncol; 1994; 22(5):299-308. PubMed ID: 8127253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.